RxDoctor Payments Data

William Merhi, DO

Interventional Cardiology · Grand Rapids, MINPI 1386786044

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $86,500 of the $114,238 with a category attached, or 75.7%. Medtronic accounts for 91.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $38,312 and has fallen 93.5% since, to $2,485 in 2025.

$114,238in general payments, 2019–2025

Across 252 payments — averaging $453.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$105K
  • Abbott$4K
  • Edwards Lifesciences$3K
  • Ancora Heart, Inc.$1K
  • Boston Scientific$1K
  • Livanova USA, Inc.$79
  • plus $56 from 1 others
$1,862,259in research payments, 2019–2025

Across 337 payments — averaging $5525.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$1.4M
  • Boston Scientific$491K
  • Abbott$11K

What the payments were for

  • Royalty or licence$8,9988%
  • Speaking & faculty fees$86,50076%
  • Travel & lodging$9,8429%
  • Food & beverage$8,8998%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)198$104,638
Abbott29$4,050
Edwards Lifesciences13$2,814
Ancora Heart, Inc.4$1,378
Boston Scientific6$1,224
Livanova USA, Inc.1$79
Baxter Healthcare1$56

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$114,238 in reported general payments places this provider in the 85th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$102,345
Medicare patients
174
Services billed
337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban19$10,501
Prednisone24$28
Amoxicillin16$14

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →